



## **Pluristem Therapeutics Announces Pricing of Registered Direct Offering of Common Stock and Warrants**

HAIFA, Israel, June 25, 2015-- Pluristem Therapeutics Inc. (NASDAQCM:PSTI, TASE:PSTI) today announced that it has entered into definitive agreements to sell 6,800,000 shares of common stock and warrants to purchase up to 4,080,000 shares of common stock at a combined price of \$2.50 per share and related warrants. The gross proceeds from the offering are expected to be approximately \$17.0 million. The warrants have an exercise price of \$2.85 per share of common stock, are immediately exercisable and expire 5 years from the closing of this offering.

Maxim Group LLC acted as lead placement agent for the offering.

The offering is expected to close on or around June 30, 2015, subject to customary closing conditions.

The shares and warrants are being offered by Pluristem pursuant to a shelf registration statement on Form S-3 (file number: 333-199303) filed pursuant to the Securities Act of 1933, which was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC). When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at <http://www.sec.gov> or by request at Maxim Group LLC, 405 Lexington Avenue, 2<sup>nd</sup> Floor, New York, NY 10174, at 212-895-3745

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

### **About Pluristem**

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-

dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit [www.pluristem.com](http://www.pluristem.com), the content of which is not part of this press release.

### **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are used in this press release when we discuss the expected closing of this offering. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties, including closing conditions being met for the offering, that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

### **CONTACT:**

Pluristem Therapeutics Inc.

Karine Kleinhaus, MD, MPH

Divisional VP, North America

1-914-512-4109

[karinek@pluristem.com](mailto:karinek@pluristem.com)